Loading company…
Synthelis is a France-based biopharmaceutical company applying synthetic biology to therapeutic protein production.
Founded in 2011 in France, Synthelis develops biopharmaceutical solutions based on synthetic biology to enhance therapeutic protein production and streamline drug development. CEO Bruno Tillier leads the company, which has completed 4 deals to date. Its latest round took place on September 7, 2016, when it raised EUR 343,350 from investors including Alpes Capital, Casra Capital, Rhone-Alpes Creation and Viadeo, at a current valuation of EUR 1.247 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in